Northern Trust Corp grew its stake in shares of Allergan PLC. (NYSE:AGN) by 8.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,492,944 shares of the company’s stock after acquiring an additional 364,722 shares during the quarter. Northern Trust Corp owned about 1.34% of Allergan PLC. worth $1,092,189,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Waldron LP bought a new position in Allergan PLC. during the first quarter valued at approximately $348,000. World Asset Management Inc boosted its holdings in Allergan PLC. by 3.7% in the first quarter. World Asset Management Inc now owns 34,865 shares of the company’s stock worth $8,330,000 after purchasing an additional 1,235 shares during the last quarter. Morse Asset Management Inc purchased a new stake in Allergan PLC. in the first quarter worth approximately $1,584,000. UBS Asset Management Americas Inc. boosted its holdings in Allergan PLC. by 0.3% in the first quarter. UBS Asset Management Americas Inc. now owns 1,995,281 shares of the company’s stock worth $476,713,000 after purchasing an additional 5,042 shares during the last quarter. Finally, Community Bank & Trust Waco Texas boosted its holdings in Allergan PLC. by 3.0% in the first quarter. Community Bank & Trust Waco Texas now owns 6,919 shares of the company’s stock worth $1,653,000 after purchasing an additional 204 shares during the last quarter. 82.03% of the stock is currently owned by hedge funds and other institutional investors.

AGN has been the topic of several research analyst reports. Cowen and Company set a $400.00 price target on Allergan PLC. and gave the company a “buy” rating in a report on Thursday, June 8th. Citigroup Inc. reaffirmed a “buy” rating and issued a $280.00 price objective on shares of Allergan PLC. in a report on Wednesday, September 20th. Mizuho cut their price objective on Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a report on Friday, June 9th. Royal Bank Of Canada reiterated a “buy” rating and set a $285.00 price objective on shares of Allergan PLC. in a research report on Wednesday, September 6th. Finally, Cantor Fitzgerald began coverage on Allergan PLC. in a research report on Friday, June 16th. They set a “neutral” rating and a $231.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $271.84.

Shares of Allergan PLC. (AGN) opened at 209.80 on Wednesday. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The stock has a market cap of $70.14 billion, a PE ratio of 6.39 and a beta of 1.15. The company’s 50 day moving average price is $220.20 and its 200 day moving average price is $233.72.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the company earned $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. On average, analysts anticipate that Allergan PLC. will post $16.22 earnings per share for the current year.

Allergan PLC. declared that its Board of Directors has authorized a stock buyback plan on Monday, September 25th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

The company also recently announced a quarterly dividend, which was paid on Friday, September 15th. Stockholders of record on Friday, August 18th were paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s payout ratio is currently 9.95%.

ILLEGAL ACTIVITY WARNING: This report was first reported by Marea Informative and is the property of of Marea Informative. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at http://www.mareainformativa.com/allergan-plc-agn-stake-increased-by-northern-trust-corp/115315/.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.